Canada markets close in 5 hours 45 minutes

Axsome Therapeutics Inc (19X.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
69.18-0.58 (-0.83%)
As of 03:32PM CEST. Market open.
Full screen
Previous Close69.76
Open67.96
Bid68.72 x 200000
Ask69.38 x 200000
Day's Range68.98 - 69.18
52 Week Range52.38 - 92.00
Volume0
Avg. Volume149
Market Cap1.637B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Axsome Therapeutics Recognizes May as Mental Health Awareness Month

    NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today is joining the global community of mental health advocates, including Mental Health America, during May’s Mental Health Month to raise awareness of the importance of mental health as a key element of overall health. Axsome is committed to the millions of individuals living wit

  • Insider Monkey

    15 Most Black States in the US

    In this article, we will be taking a look at the 15 most black states in the US. If you do not want to learn about the demographics of global black population, head straight to the 5 Most Black States in the US. Overview of the Global Black Population: Demographics, Trends, and Immigration Patterns The […]

  • GlobeNewswire

    Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

    AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting effects of solriamfetol NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations highlighting its innovative p